Core Viewpoint - Protalix Biotherapeutics Inc is gaining attention for its focus on rare diseases and innovative treatments, with analysts suggesting it is on the verge of sustainable profitability [1][10]. Revenue Growth - The company's flagship drug, Elfabrio, is driving revenue growth, particularly as a treatment for Fabry disease, a rare genetic disorder [2][3]. - Elfabrio is gaining traction globally through commercialization partner Chiesi Global Rare Diseases, with analysts projecting sustainable profitability primarily from Elfabrio's royalty stream [3][10]. Competitive Advantages - Elfabrio offers competitive advantages over existing treatments, including a longer presence in the bloodstream and reduced immune response [4]. Established Treatments - Protalix also has a significant presence in treating Gaucher disease with its drug Elelyso, which maintains a 25% market share in Brazil [5]. Unique Production Platform - The company's proprietary ProCellEx platform allows for the production of biologic drugs using plant cells, offering a simplified manufacturing process and natural viral resistance [6][7]. Pipeline Expansion - Protalix is advancing PRX-115, a drug designed to treat uncontrolled gout, with promising Phase 1 results and a Phase 2 trial expected in the second half of 2025 [8][10]. Financial Position - The company has improved its financial position by eliminating $65 million in debt over the last five years and holding over $27 million in cash as of September 30, 2024 [9][10]. Future Growth Potential - Analysts believe Protalix's revenue streams and drug pipeline position it for substantial upside, with potential exponential increases in value if PRX-115's Phase 2 results are favorable [10][11]. Research and Development - Protalix is exploring early-stage research into rare renal diseases and additional lysosomal disorders, targeting therapies that address unmet medical needs [11][12]. Market Position - Protalix has demonstrated its ability to develop and commercialize treatments for rare diseases, a notable achievement for small-cap biotech firms [13][14].

Group 1 - Pluxee N.V. disclosed transactions on treasury shares from February 11 to February 14, 2025, detailing daily volumes and average prices [1] - The total number of shares acquired on February 11 was 21,549 shares at an average price of €22.55 [1] - On February 12, a total of 33,925 shares were acquired at an average price of €22.41 [1] - The transactions on February 13 totaled 33,140 shares at an average price of €22.60 [1] - On February 14, 35,660 shares were acquired at an average price of €22.77 [1] Group 2 - Pluxee operates in 29 countries, focusing on Employee Benefits and Engagement, with a client base of over 500,000 and more than 37 million consumers [2] - The company has been in business for over 45 years and employs more than 5,400 team members [2] - Pluxee's solutions include Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits, aimed at attracting and retaining talent [2]

Core Viewpoint - Pluxee has announced a share buy-back program of up to 15 million euros to support its performance share allocation plan, effective from February 11, 2025, until May 30, 2025 [1][2]. Group 1: Share Buy-Back Program - The share buy-back program will be executed in compliance with the authorization from the General meeting of shareholders and relevant market regulations [1][2]. - The shares repurchased will be held as treasury stock solely to fulfill the company's obligations under its performance share plan [2]. Group 2: Company Overview - Pluxee operates globally in the Employee Benefits and Engagement sector across 29 countries, providing solutions in Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [3]. - The company has over 5,400 engaged team members and serves more than 500,000 clients, 37 million consumers, and 1.7 million merchants [3]. - With over 45 years of experience, Pluxee is dedicated to positively impacting local communities and promoting employee well-being while also focusing on environmental protection [3].

Group 1 - Proactive specializes in providing fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive has a strong emphasis on technology adoption, utilizing both human expertise and technological tools to enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Company Overview - Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system [4] - The company is notable for being the first to receive FDA approval for a protein produced through a plant cell-based suspension expression system [4] - Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa, its first product, to Pfizer Inc., while retaining full rights in Brazil [4] Recent Developments - Protalix will present at the 2025 BIO CEO & Investor Conference on February 11, 2025, at 10:15 AM EST [1][2] - The company’s second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023 [4] - Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio [5] Product Pipeline - Protalix's development pipeline includes proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets, such as: - PRX–115: a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout [5] - PRX–119: a plant cell-expressed long-action DNase I for NETs-related diseases [5]

Company Overview - Pluxee is a global leader in Employee Benefits and Engagement, operating in 29 countries with a focus on Meal & Food, Wellbeing, Lifestyle, Reward & Recognition, and Public Benefits [2] - The company serves over 500,000 clients, 37 million+ consumers, and 1.7 million+ merchants, supported by more than 5,000 team members and advanced technology [2] - Pluxee has been in business for over 45 years, emphasizing positive community impact, employee wellbeing, and environmental sustainability [2] Liquidity Contract Summary - As of December 31, 2024, the liquidity account held 200,439 Pluxee N.V. ordinary shares valued at €5,878,911 [4] - During the period from July 1, 2024, to December 31, 2024, the company purchased 972,323 ordinary shares worth €19,626,472 across 6,377 transactions and disposed of 848,300 ordinary shares worth €17,195,841 across 5,661 transactions [4] - In the previous half-yearly report as of June 30, 2024, the liquidity account held 59,130 Pluxee N.V. ordinary shares valued at €8,621,644 [4] - From January 31, 2024, to June 30, 2024, the company purchased 723,308 ordinary shares worth €19,930,588 across 5,132 transactions and disposed of 719,315 ordinary shares worth €19,933,554 across 4,627 transactions [4] - The liquidity account started with €10,000,000 as of January 31, 2024 [4]

Core Insights - The company reported a strong start to Fiscal Q1 2025, achieving total revenues of 289 million euros, representing a 13.2% organic growth year-on-year, driven by robust performance in Employee Benefits and Float revenue [2][9][6] Financial Performance - Operating revenue reached 249 million euros, with a 12.1% organic growth compared to the previous year, primarily fueled by Employee Benefits which saw a 14.9% organic growth [10][12] - Float revenue amounted to 40 million euros, reflecting a 20.9% organic growth year-on-year, supported by an increasing Float base and improved average investment yield [11][6] - Total business volumes issued in the first quarter reached 6.5 billion euros, up from 6.1 billion euros in the same period last year [5] Regional Performance - Continental Europe generated operating revenue of 105 million euros, showing a 9.7% organic growth, while Latin America reported 98 million euros with an 11.1% organic growth [15][16] - The Rest of the World segment achieved 46 million euros in operating revenue, reflecting a significant 20.0% organic growth, driven by increased adoption of Pluxee solutions [17] Business Segments - Employee Benefits accounted for 212 million euros in operating revenue, with a 14.9% organic growth, indicating strong commercial dynamics and client retention [12][33] - Other products and services generated 37 million euros, experiencing a slight decline of 2.6% organically, impacted by a contract discontinuation in Chile [13][31] M&A and Strategic Initiatives - The company is actively pursuing M&A opportunities, including the acquisition of Benefício Fácil, a leader in employee mobility benefits in Brazil, expected to enhance organic growth [20][19] - The partnership with Santander in Brazil is progressing well, with approximately 90% of business volume migration completed, contributing to significant new client wins [21][19] Outlook - The company reaffirms its financial objectives for Fiscal 2025 and 2026, targeting low double-digit organic revenue growth and further expansion of the Recurring EBITDA margin [24][27]

Core Viewpoint - Protalix BioTherapeutics is making significant progress in its development pipeline and commercial partnerships, particularly with Chiesi Global Rare Diseases, to enhance treatment options for patients with rare diseases like Fabry disease [1][5][10]. Group 1: Company Developments - Protalix has achieved important milestones in 2024, including the validation of a less frequent dosing regimen for pegunigalsidase alfa by the European Medicine Agency [1]. - The company has successfully completed a Phase I First-in-Human clinical trial for PRX-115, demonstrating its potential as a safe and effective treatment for uncontrolled gout, with plans to advance to Phase II trials in the second half of 2025 [10]. - Protalix has repaid all outstanding convertible notes, resulting in a debt-free status, which strengthens its financial position for ongoing operations [12]. Group 2: Product Pipeline - The development pipeline includes proprietary recombinant therapeutic proteins targeting established pharmaceutical markets, such as PRX-115 for gout and PRX-119 for NETs-related diseases [5][11]. - Elfabrio®, the company's second product, received FDA and EMA approval in May 2023, marking a significant achievement in its product portfolio [16]. Group 3: Partnerships and Collaborations - Protalix's collaboration with Chiesi Farmaceutici S.p.A. is crucial for the global development and commercialization of Elfabrio, highlighting the importance of strategic partnerships in the company's growth [5][1]. - The partnership aims to reduce the treatment burden for patients with Fabry disease, showcasing a commitment to patient-centered care [1].

Company Overview - Pluxee is a global player in employee benefits and engagement, operating in 29 countries [3] - The company offers a broad range of solutions across Meal & Food, Wellbeing, Lifestyle, Reward & Recognition, and Public Benefits [3] - Pluxee has over 5,400 engaged team members and serves more than 500,000 clients, 37 million consumers, and 1.7 million merchants [3] - The company has been a trusted partner for over 45 years, focusing on positive impacts for stakeholders and supporting employee wellbeing [3] Annual General Meeting Highlights - The Annual General Meeting of Shareholders was held on December 18, 2024, in Amsterdam-Schiphol [1] - All resolutions on the agenda were approved, including the adoption of financial statements for Fiscal 2024 [2] - A dividend distribution of EUR 0.35 per ordinary share was approved, with the ex-dividend date set for December 20, 2024, record date on December 23, 2024, and payment date on December 24, 2024 [2] - The meeting was broadcast live, and detailed voting results will be available on the Pluxee Group website [2]

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q3 2024 Results Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - President and Chief Executive Officer Eyal Rubin - Senior Vice President and Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Investment Research Daniel Smith - H.C. Wainwright & Co., LLC Robert Sassoon - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to ...